MannKind raises $50M to fund $45M CVR payment triggered by Furoscix ReadyFlow FDA approval

Filed July 24, 2026 · Period ending July 23, 2026 · ~1 min read

Key Changes

• high

  FDA approved Furoscix ReadyFlow (furosemide injection) for treating edema in adults with heart failure or chronic kidney disease, opening a new revenue stream in cardiovascular and renal markets.

  Item 8.01 verify on EDGAR →
• high

  MannKind raised $50M gross proceeds via private placement of 10.4M common shares at $3.89 and pre-funded warrants for 2.4M shares at $3.88, representing ~12.9M shares of potential dilution.

  Item 3.02 verify on EDGAR →
• high

  Net proceeds will fund a $45M contingent value rights payment triggered by the Furoscix ReadyFlow approval and general corporate purposes.

  Item 3.02 verify on EDGAR →